Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tadalafil oral film - Aquestive Therapeutics

Next Previous
Drug Profile

Tadalafil oral film - Aquestive Therapeutics

Alternative Names: AQST-119; Exordia

Latest Information Update: 15 Feb 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MonoSol Rx
  • Developer Aquestive Therapeutics
  • Class Antihypertensives; Benzodioxoles; Carbolines; Erectile dysfunction therapies; Gastrokinetics; Heart failure therapies; Indoles; Ischaemic heart disorder therapies; Pyridones; Small molecules; Vascular disorder therapies; Vasodilators
  • Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Erectile dysfunction

Most Recent Events

  • 15 Feb 2022 Tadalafil is still in preregistration stage for Erectile dysfunction in USA (Aquestive Therapeutics pipeline, February 2022)
  • 29 Sep 2021 Aquestive Therapeutics and IntelGenx Corp. enter into an definitive license and supply agreement with an Undisclosed company to market tadalafil oral films for Erectile dysfunction and Benign prostatic hyperplasia in USA
  • 01 Sep 2019 IntelGenx plans to launch tadalafil oral film for the treatment of Erectile dysfunction in USA, in 2021

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top